drugset / Trial / NCT02087579

Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants

NCT02087579

Phase 1 Completed 305 enrolled Janssen Research & Development, LLC
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The purpose of this study is to gather information about the steady-state plasma concentrations of aripiprazole, olanzapine, quetiapine and their relevant metabolites, at various dose levels and at different time points after dosing. In addition, comparison of capillary drug concentrations vs. venous drug concentrations will be performed for aripiprazole, olanzapine, paliperidone, quetiapine, risperidone and their relevant metabolites.

Timeline

Start
2014-02
Primary completion
2014-10
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Aripiprazole Other / unclassified Oral
Subject Olanzapine Small molecule Oral
Subject Paliperidone Unknown Oral
Subject Paliperidone Unknown Other
Subject Quetiapine Small molecule Oral
Subject Risperidone Other / unclassified Oral
Subject Risperidone Other / unclassified Other